("Scancell" or the "Company")
Director Dealing
Scancell (AIM: SCLP), the developer of novel immunotherapy products for the treatment of multiple cancers, announces that
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||||||
|
a) |
|
|
|||||||||
|
2 |
Reason for the notification |
||||||||||
|
a) |
Position/status |
Fund closely associated with |
|||||||||
|
b) |
Initial notification/Amendment |
Initial notification |
|||||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||||||
|
a) |
|
|
|||||||||
|
b) |
LEI |
2138008RXEG856SNP666 |
|||||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary Shares of |
|||||||||
|
b) |
Identification Code |
GB00B63D3314 |
|||||||||
|
c) |
Nature of the transaction |
Purchase of Ordinary Shares |
|||||||||
|
|
|
|
|||||||||
|
d) |
Price(s) and volume(s) |
|
|||||||||
|
e) |
Aggregated information - Aggregated volume - Price |
497,764 Ordinary Shares |
|||||||||
|
f) |
Date of the transaction |
|
|||||||||
|
g) |
Place of the transaction |
|
|||||||||
|
For further information, please contact: |
|
|
|
|
|
|
+44 (0) 20 3709 5700 |
|
|
|
|
Sath Nirmalananthan, CFO |
|
|
Dr |
|
|
|
|
|
Panmure Liberum (Nominated Adviser and Joint Broker) |
+44 (0) 20 7886 2500 |
|
|
|
|
|
|
|
|
+44 (0) 20 3705 9330
|
|
|
|
|
|
+44 (0) 20 3709 5700 |
About Scancell
Scancell (LSE:SCLP) develops immunotherapies for a Cancer-free future by enhancing long-lasting tumour specific immunity. As a clinical stage biotechnology company with deep roots in cancer immunology and translational research, Scancell develops tumour targeted off-the-shelf vaccines, with highly favourable safety and durable systemic immune responses. Scancell's lead product, iSCIB1+, a DNA vaccine, is currently showing strong promise on top of checkpoint therapies in a multi-arm phase 2 study in first-line melanoma. The second vaccine, Modi-1, is being investigated in a phase 2 study in a broad range of solid tumours. Scancell is also developing a pipeline of high affinity antibodies targeting tumour specific glycans using its proprietary platforms. Two of these antibodies are now being developed in major biopharma partnerships, and a further two antibodies targeting lung and epithelial cancers are actively being developed in-house.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the